Merve Alaylıoğlu

The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease

Erdinç Dursun, Duygu Gezen‐Ak, Haşmet Hanağası et al. · Journal of Neuroimmunology · 2015 · 230 citations

Medicine, Immunology, Neurology +17

BDNF, TNFα, HSP90, CFH, and IL-10 Serum Levels in Patients with Early or Late Onset Alzheimer's Disease or Mild Cognitive Impairment

Duygu Gezen‐Ak, Erdinç Dursun, Haşmet Hanağası et al. · Journal of Alzheimer s Disease · 2013 · 185 citations

Life Sciences, Neurology, Neuroscience +17

Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Mustafa Sait Gönen, Merve Alaylıoğlu, Emre Durcan et al. · Nutrients · 2021 · 73 citations · Full text

Medicine, Infectious Diseases, Nutritional Sciences +17

GC and VDR SNPs and Vitamin D Levels in Parkinson’s Disease: The Relevance to Clinical Features

Duygu Gezen‐Ak, Merve Alaylıoğlu, Gençer Genç et al. · NeuroMolecular Medicine · 2016 · 52 citations

Medicine, Molecular Genetics, Neurology +17

Vitamin D Receptor Regulates Amyloid Beta 1–42 Production with Protein Disulfide Isomerase A3

Duygu Gezen‐Ak, İrem L. Atasoy, Esin Candaş et al. · ACS Chemical Neuroscience · 2017 · 48 citations

Life Sciences, Neurobiology, Neuroscience +17